Gan Jingyi, Meng Fanwei, Zhou Xin, Li Chan, He Yixin, Zeng Xiaoping, Jiang Xingen, Liu Jia, Zeng Guifang, Tang Yunxia, Liu Muyun, Mrsny Randall J, Hu Xiang, Hu Jifan, Li Tao
Shenzhen Beike Cell Engineering Research Institute, Yuanxing Science and Technology Building, Nanshan, Shenzhen, China.
GMR Epigenetics, Palo Alto, California, USA; Department of Pharmacy & Pharmacology, University of Bath, Bath, England.
Cytotherapy. 2015 Apr;17(4):403-17. doi: 10.1016/j.jcyt.2014.11.011. Epub 2015 Jan 21.
Acute radiation syndrome (ARS) leads to pancytopenia and multi-organ failure. Transplantation of hematopoietic stem cells provides a curative option for radiation-induced aplasia, but this therapy is limited by donor availability.
We examined an alternative therapeutic approach to ARS with the use of human extracellular superoxide dismutase (ECSOD)-modified umbilical cord mesenchymal stromal cells (UCMSCs). This treatment combines the unique regenerative role of UCMSCs with the anti-oxidative activity of ECSOD.
We demonstrated that systemically administered ECSOD-UCMSCs are able to protect mice from sub-lethal doses of radiation and improve survival by promoting multilineage hematopoietic recovery. The therapeutic effect of this treatment is related to the decrease in radiation-induced O(2)(-) and apoptosis.
Our data highlight the clinical potential of this two-pronged approach to the treatment of ARS, thereby serving as a rapid and effective first-line strategy to combat the hematopoietic failure resulting from a radiation accident, nuclear terrorism and other radiologic emergencies.
急性放射综合征（ARS）可导致全血细胞减少和多器官功能衰竭。造血干细胞移植为辐射诱导的再生障碍提供了一种治愈选择，但这种疗法受到供体可用性的限制。
我们研究了一种使用人细胞外超氧化物歧化酶（ECSOD）修饰的脐带间充质基质细胞（UCMSCs）治疗ARS的替代方法。这种治疗方法将UCMSCs独特的再生作用与ECSOD的抗氧化活性相结合。
我们证明，全身给药的ECSOD-UCMSCs能够保护小鼠免受亚致死剂量辐射，并通过促进多谱系造血恢复来提高存活率。这种治疗的疗效与辐射诱导的超氧阴离子（O₂⁻）减少和细胞凋亡有关。
我们的数据突出了这种双管齐下治疗ARS方法的临床潜力，从而成为应对辐射事故、核恐怖主义及其他放射紧急情况导致的造血功能衰竭的快速有效一线策略。
